Despite encouraging results from a preclinical testing, the selective PDE inhibitors are used sporadically in patients with ARDS or sepsis (Table 3), except for the ongoing studies on COVID-19 (see Chapter 7). This evidence concerns the gene ALDH7A1 and acute respiratory distress syndrome.